By Jaime Llinares Taboada
Shares in Arecor Therapeutics PLC climbed Monday morning after its polysaccharide vaccine patent was upheld by the European Patent Office.
The EPO was considering an appeal filed by GlaxoSmithKline PLC, but this was dismissed.
Arecor said its patent protects novel compositions of a specific type of vaccines, called polysaccharide vaccines, which are used to prevent degradation.
Polysaccharide vaccines are used to protect against diseases such as meningitis and pneumonia.
Shares at 0855 GMT were up 9.2% at 415 pence.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT
(END) Dow Jones Newswires
10-11-21 0519ET